| Drug General Information |
| Drug ID |
D0S9IE
|
| Former ID |
DIB001571
|
| Drug Name |
BAY1125976
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 1 |
[524391]
|
|---|
| Company |
Bayer healthcare pharmaceuticals
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
AKT3 protein kinase |
Target Info |
Modulator |
[1572591]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Sphingolipid signaling pathway
|
|
mTOR signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Apoptosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
VEGF signaling pathway
|
|
Osteoclast differentiation
|
|
Focal adhesion
|
|
Tight junction
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Platelet activation
|
|
Toll-like receptor signaling pathway
|
|
Jak-STAT signaling pathway
|
|
T cell receptor signaling pathway
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
TNF signaling pathway
|
|
Neurotrophin signaling pathway
|
|
Cholinergic synapse
|
|
Dopaminergic synapse
|
|
Insulin signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Glucagon signaling pathway
|
|
Regulation of lipolysis in adipocytes
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Carbohydrate digestion and absorption
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
Measles
|
|
Influenza A
|
|
HTLV-I infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
Colorectal cancer
|
|
Renal cell carcinoma
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
Chronic myeloid leukemia
|
|
Acute myeloid leukemia
|
|
Small cell lung cancer
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancer
|
|
NetPath Pathway
|
TSH Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Apoptosis signaling pathway
|
|
EGF receptor signaling pathway
|
|
Endothelin signaling pathway
|
|
FGF signaling pathway
|
|
Huntington disease
|
|
Hypoxia response via HIF activation
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Interleukin signaling pathway
|
|
PI3 kinase pathway
|
|
T cell activation
|
|
p53 pathway
|
|
Ras Pathway
|
|
p53 pathway by glucose deprivation
|
|
p53 pathway feedback loops 2
|
|
Pathway Interaction Database
|
S1P3 pathway
|
|
Class I PI3K signaling events mediated by Akt
|
| References |
| Ref 524391 | ClinicalTrials.gov (NCT01915576) Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients. U.S. National Institutes of Health. |
|---|
| Ref 1572591 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. |
|---|
